FierceBiotechOriginal article
{"a":[{"_":"Cullinan tees up J&J fight—and $100M payday—as Taiho-partnered drug hits phase 3 cancer goal","$":{"href":"/biotech/cullinan-tees-jj-fight-and-100m-payday-taiho-partnered-drug-hits-cancer-goal","hreflang":"en"}}]}
Phase 3positivePositive
AI Analysis
Summary
Taiho Pharmaceutical and Cullinan Therapeutics achieved a second phase 3 victory for their small-molecule EGFR inhibitor in lung cancer, positioning the partners to compete with Johnson & Johnson in this therapeutic niche.
Clinical Trial Data
Phase
3
Primary Endpoint
Met
Outcome Details
second phase 3 victory for small-molecule EGFR inhibitor
Importance:7/10
Sentiment:
0.80
phase 3EGFR inhibitorlung cancerpartnershipclinical trial
Related Companies
Read the original article
Published by FierceBiotech on August 13, 2026 5:26 AM